• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Synthetic Biologics fills irritable bowel syndrome Clinical Advisory Board

Synthetic Biologics fills irritable bowel syndrome Clinical Advisory Board

October 16, 2014
CenterWatch Staff

Synthetic Biologics, a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases, has expanded its Clinical Advisory Board (CAB) created to support development of SYN-010, the company's statin-class candidate intended to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS).

The C-IBS CAB, chaired by Mark Pimentel, M.D., director of the GI Motility Program and Laboratory at Cedars-Sinai Medical Center, is strengthened by the addition of four new members. The valuable guidance provided by the C-IBS CAB has focused the clinical development of SYN-010, which is anticipated to initiate a phase II clinical trial in C-IBS during the first half of 2015 under a corporate Investigational New Drug (IND) application, with top line data expected in mid-2015.

William Chey, M.D., is a professor of medicine, director of the GI Physiology Laboratory, and co-director of the Michigan Bowel Control Program at the University of Michigan. Chey's clinical and research interests include: diagnosis and treatment of irritable bowel syndrome (IBS), constipation and fecal incontinence; gastroesophageal reflux disease (GERD); and "H. pylori" infection.

Gail M. Comer, M.D., a board-certified gastroenterologist and hepatologist, has more than 16 years of experience in the pharmaceutical industry, having spent seven years at Abbott Laboratories as a medical director, six years in clinical development at Wyeth Research as senior medical director, senior director of the BioTherapeutics Research Unit at Pfizer. She also was the chief medical officer at Synergy Pharmaceuticals before starting her own consulting business. Comer has focused primarily on gastrointestinal and inflammatory disorders.

Anthony J. Lembo, M.D., is associate professor of medicine at Harvard Medical School. He also is the director of the GI Motility Laboratory at the Beth Israel Deaconess Medical Center's (BIDMC) Division of Gastroenterology in Boston, Mass.

Philip Schoenfeld, M.D., MSEd, MSc, is professor of medicine at the University of Michigan School of Medicine, director of the University's Gastrointestinal Epidemiology Training Program and staff physician in UM's Specialized Functional Bowel Disorder Program. He currently is associate editor of gastroenterology, past associate editor (Colon) for the American Journal of Gastroenterology, past chair of the AGA's Education Committee, past chair of the AGA's Clinical Practice Section.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing